Carbetocin Market: Current Analysis and Forecast (2022-2030)

Carbetocin is a synthetic hormone used to prevent postpartum hemorrhage (PPH) in women who have just given birth. It works by stimulating contractions in the uterus to prevent excessive bleeding. Carbetocin is administered as an injection and is typically given after vaginal delivery or after a cesarean section. The market for carbetocin is expected to witness growth due to the increasing number of pregnancies and high fertility rate globally. For instance, as per the World Bank, in 2020, the global fertility rate of births per woman accounted for 2.3 and is expected to reach 2.1 by year 2050.

Carbetocin Market is expected to grow at a strong CAGR of 5% during the forecast period owing to the frequent product launches. For instance, In September 2021, Abbott Laboratory launched a single-dose formulation of carbetocin to prevent post partem hemorrhage.

Based on type, the market is segmented into original drug and generic drug. As per our analysis, the diagnosis segment acquired a major share in 2021. Duratocin is the original and the most widely used brand of carbetocin, and it is available in many countries around the world. This is mainly due to the high popularity of the brand and the quality of the brand offered by the companies attributes to the large share of the segment.

Based on the end-user, the market is segmented into hospitals, clinics, and others. The clinics segment is expected to grow with a higher CAGR in the carbetocin market during the forecast period. The maternity clinics have specialized professionals for gynae treatments is the main reason for the fast growth of the segment in the carbetocin market.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North American region held the dominant share of the carbetocin market in 2021. This is mainly due to the presence of major economies such as the U.S., along with the high healthcare spending is the main reason for the market growth of the region in the carbetocin market. For example, as per the Canadian Institute for Health Information, total health spending in Canada was around USD 331 billion in 2022 and per capita expenditure in Canada accounted for USD 8563.

Some of the major players operating in the market include: Ferring B.V.; Hybio Pharmaceutical Co., Ltd.; Pfizer Inc.; Beacon Pharmaceuticals Limited; SGPharma Pvt. Ltd.; Taj Pharmaceuticals; Abbott; MANUS AKTTEVA BIOPHARMA LLP; Enomark; and Sun Pharmaceutical Industries Ltd.